IL6 and Hyperbilirubinemia: The results of this study suggested that PGC-CDs could inhibit levels of IL-6 and TNF-α in the treatment of hyperbilirubinemia and its associated liver damage, thereby reducing the mortality of hyperbilirubinemia.